tiprankstipranks
Trending News
More News >

Hansoh Pharmaceutical’s Aumolertinib Mesilate Tablets Approved for UK Market

Story Highlights
Hansoh Pharmaceutical’s Aumolertinib Mesilate Tablets Approved for UK Market

Don’t Miss TipRanks’ Half-Year Sale

Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ) has provided an update.

Hansoh Pharmaceutical Group Company Limited announced that its innovative drug, Aumolertinib Mesilate Tablets, has been approved by the UK’s Medicines and Healthcare Products Regulatory Agency for marketing. This approval marks a significant milestone for the company as it expands its market presence in the UK, offering treatment options for patients with specific mutations of non-small cell lung cancer. The approval is expected to enhance the company’s position in the pharmaceutical industry and provide new opportunities for growth.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$22.06 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

More about Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company incorporated in the Cayman Islands, primarily focused on developing innovative drugs. The company is known for its work in the treatment of non-small cell lung cancer (NSCLC) and has developed Aumolertinib Mesilate Tablets, a third-generation EGFR-TKI drug.

Average Trading Volume: 12,287,391

Technical Sentiment Signal: Buy

Current Market Cap: HK$154.6B

For a thorough assessment of 3692 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1